Genprex shares are trading higher after the company announced it has advanced to the highest dose group in its Acclaim-3 trial for Reqorsa Gene Therapy with Tecentriq after receiving a safety review committee approval.
Portfolio Pulse from Benzinga Newsdesk
Genprex shares rose as the company advanced to the highest dose group in its Acclaim-3 trial for Reqorsa Gene Therapy with Tecentriq, following safety review committee approval.
October 15, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex shares increased after advancing to the highest dose group in its Acclaim-3 trial for Reqorsa Gene Therapy with Tecentriq, following safety approval.
The advancement to the highest dose group in a clinical trial is a significant milestone, indicating positive progress and safety in the trial. This news likely boosts investor confidence, leading to a rise in Genprex's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100